

# FOOD AND DRUG ADMINISTRATION

Center for Biologics Evaluation and Research  
118<sup>th</sup> Meeting of the Blood Products Advisory Committee  
Blood Products Advisory Committee  
Great Room, Building 31  
FDA White Oak Campus  
10903 New Hampshire Avenue  
Silver Spring, MD 20993

June 22, 2018

## DRAFT AGENDA

June 22, 2018

11:00 a.m.	Call to Order and Opening Remarks Introduction of Committee	Suzette Priola, Ph.D. Acting Chair
11:10 a.m.	Conflict of Interest Statement	Bryan Emery, LCDR Designated Federal Officer

**Topic I: Review of the Research Programs in the Laboratories of Emerging Pathogens, Bacterial and Transmissible Spongiform Encephalopathy Agents, and Molecular Virology, Division of Emerging Transfusion-Transmitted Diseases (DETTD), Office of Blood Research and Review (OBRR)**

11:15 a.m.	Overview of CBER Research Programs	Carolyn Wilson, Ph.D. CBER, FDA (10')
11:25 a.m.	Overview of OBRR Research Programs	CD Atreya, Ph.D. OBRR, FDA (10')
11:35 a.m.	Overview of DETTD Research Programs	Hira Nakhasi, Ph.D. OBRR, FDA (40')
12:15 p.m.	Questions for the Speakers	(10')
12:25 p.m.	Open Public Hearing	(30')
12:55 p.m.	Closed Committee Discussion	(45')
1:40 p.m.	Break/ Lunch	(40')

**Topic II: Review of the Research Program of the Hemostasis Branch (HB), Division of Plasma Protein Therapeutics (DPPT), Office of Tissues and Advanced Therapies (OTAT)**

2:20 p.m.	Overview of OTAT Research Programs	Suzanne Epstein, Ph.D. OTAT, FDA (10')
-----------	------------------------------------	---

6/19/18

# FOOD AND DRUG ADMINISTRATION

Center for Biologics Evaluation and Research  
118<sup>th</sup> Meeting of the Blood Products Advisory Committee  
Blood Products Advisory Committee  
Great Room, Building 31  
FDA White Oak Campus  
10903 New Hampshire Avenue  
Silver Spring, MD 20993

June 22, 2018

## DRAFT AGENDA

2:30 p.m.	Overview of the DPPT Research Programs	Basil Golding, Ph.D. OTAT, FDA (10')
2:40 p.m.	Overview of the HB Research Program Research Program	Timothy Lee, Ph.D. OTAT, FDA (25')
3:05 p.m.	Questions for the Speakers	(10')
3:15 p.m.	Open Public Hearing	(30')
3:45 p.m.	Closed Committee Discussion	(35')
4:20 p.m.	Adjournment	